Valuation: Bicycle Therapeutics plc

Market Cap 249M 221M 207M 189M 355M 23.99B 360M 2.5B 969M 12.22B 936M 915M 39.24B P/E 2026 *
-1.37x
P/E 2027 * -1.52x
Enterprise Value -264M -234M -219M -200M -376M -25.38B -381M -2.65B -1.03B -12.93B -990M -968M -41.52B EV / Sales 2026 *
-15x
EV / Sales 2027 * -23.1x
Free-Float
71.25%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
1 week-4.56%
Current month-3.26%
1 month-13.17%
3 months-15.44%
6 months-27.35%
Current year-49.72%
1 week 3.55
Extreme 3.55
3.81
1 month 3.55
Extreme 3.55
4.36
Current year 3.55
Extreme 3.55
7.34
1 year 3.55
Extreme 3.55
9.16
3 years 3.55
Extreme 3.55
28.67
5 years 3.55
Extreme 3.55
62.08
10 years 3.55
Extreme 3.55
62.08
Manager TitleAgeSince
Chief Executive Officer 57 01/09/2015
Director of Finance/CFO 46 29/01/2026
Chief Tech/Sci/R&D Officer - 01/06/2025
Director TitleAgeSince
Director/Board Member 57 01/09/2015
Director/Board Member 63 17/03/2021
Director/Board Member 69 20/02/2024
Date Insider Type Main position Quantity % Market Cap. Importance
15/07/26 Free

CHIEF PROD & SUPPLY CHAIN OFF

60,000 0.1580%
15/07/26 Free

Chief Technology Officer

60,000 0.1580%
15/07/26 Free

Chief Operating Officer

60,000 0.1580%
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%-4.56%-57.26%-82.28% 249M
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.61%+0.81%+27.25%+82.72% 59.26B
-2.54%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-3.39%+2.26%+28.80%+21.93% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -1.18%-0.93%+42.08%+130.54% 39.27B
Weighted average by Cap. -0.39%-0.32%+58.37%+145.90%

Financials

2026 *2027 *
Net sales 17.53M 15.57M 14.56M 13.27M 24.98M 1.69B 25.33M 176M 68.2M 860M 65.83M 64.4M 2.76B 6.69M 5.94M 5.56M 5.06M 9.53M 644M 9.66M 67.21M 26.02M 328M 25.11M 24.57M 1.05B
Net income -172M -153M -143M -130M -245M -16.57B -249M -1.73B -669M -8.44B -646M -632M -27.1B -175M -156M -145M -133M -250M -16.86B -253M -1.76B -681M -8.59B -657M -643M -27.58B
Net Debt -513M -455M -426M -388M -731M -49.37B -741M -5.15B -1.99B -25.15B -1.93B -1.88B -80.76B -403M -358M -335M -305M -575M -38.83B -583M -4.05B -1.57B -19.78B -1.51B -1.48B -63.53B
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
01/10/26 $3.560 -3.26% 379,977
30/09/26 $3.680 +0.82% 295,138
29/09/26 $3.650 -1.62% 206,180
28/09/26 $3.710 +0.68% 442,525
25/09/26 $3.685 -1.21% 238,876
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.560USD
Average target price
9.500USD
Spread / Average Target
+166.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BCYC Stock